Cardiovascular Research Center, Health Institute, Imam-Ali hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Health Education and Health Promotion, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Arch Iran Med. 2021 Nov 1;24(11):796-803. doi: 10.34172/aim.2021.119.
Considerable variability in survival rate after ST-segment elevation myocardial infarction (STEMI) is present and outcomes remain suboptimal, especially in low- and middle-income contraries. This study aimed to investigate predictors of 30- day mortality after STEMI, including reperfusion therapy, in a tertiary hospital in western Iran.
In this registry-based cohort study (2016-2019), we investigated reperfusion therapies - primary percutaneous coronary intervention (PPCI), pharmaco-invasive (thrombolysis followed by angiography/percutaneous coronary intervention), and thrombolysis alone - used in Imam-Ali hospital, the only hospital with a PPCI capability in the Kermanshah Province. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs), using Cox proportional-hazard models, to investigate the potential predictors of 30-day mortality including reperfusion therapy, admission types (direct admission/referral from non-PPCI-capable hospitals), demographic variables, coronary risk factors, vital signs on admission, medical history, and laboratory tests.
Data of 2428 STEMI patients (mean age: 60.73; 22.9% female) were available. Reperfusion therapy was performed in 84% of patients (58% PPCI, 10% pharmaco-invasive, 16% thrombolysis alone). Only 17% of the referred patients had received thrombolysis at non-PPCI-capable hospitals. Among patients with thrombolysis, only 38.2% underwent coronary angiography/ percutaneous coronary intervention. The independent predictors of mortality were: no reperfusion therapy (HR: 2.01, 95% CI: 1.36-2.97), referral from non-PPCI-capable hospitals (1.73, 1.22-2.46), age (1.03, 1.01-1.04), glomerular filtration rate (0.97, 0.96-0.97), heart rate>100 bpm (1.94, 1.22-3.08), and systolic blood pressure<100 mm Hg (4.92, 3.43-7.04). Mortality was lower with the pharmaco-invasive approach, although statistically non-significant, than other reperfusion therapies.
Reperfusion therapy, admission types, age, glomerular filtration rate, heart rate, and blood pressure were independently associated with 30-day mortality. Using a comprehensive STEMI network to increase reperfusion therapy, especially pharmaco-invasive therapy, is recommended.
ST 段抬高型心肌梗死(STEMI)后的生存率存在相当大的差异,治疗效果仍不理想,尤其是在中低收入国家。本研究旨在调查伊朗西部一家三级医院 STEMI 后 30 天死亡率的预测因素,包括再灌注治疗。
本注册队列研究(2016-2019 年)调查了伊玛目阿里医院使用的再灌注治疗方法-直接经皮冠状动脉介入治疗(PPCI)、药物溶栓后血管造影/经皮冠状动脉介入治疗(药物溶栓联合 PPCI)和单纯溶栓。我们使用 Cox 比例风险模型估计了 30 天死亡率的潜在预测因素,包括再灌注治疗、入院类型(直接入院/非 PPCI 能力医院转诊)、人口统计学变量、冠心病危险因素、入院时生命体征、既往病史和实验室检查。
共纳入 2428 例 STEMI 患者(平均年龄:60.73 岁,22.9%为女性)。84%的患者接受了再灌注治疗(58%接受 PPCI,10%接受药物溶栓联合 PPCI,16%接受单纯溶栓)。只有 17%的转诊患者在非 PPCI 能力医院接受了溶栓治疗。在接受溶栓治疗的患者中,只有 38.2%接受了冠状动脉造影/经皮冠状动脉介入治疗。死亡率的独立预测因素包括:未进行再灌注治疗(HR:2.01,95%CI:1.36-2.97)、来自非 PPCI 能力医院的转诊(1.73,1.22-2.46)、年龄(1.03,1.01-1.04)、肾小球滤过率(0.97,0.96-0.97)、心率>100 bpm(1.94,1.22-3.08)和收缩压<100 mm Hg(4.92,3.43-7.04)。虽然药物溶栓联合 PPCI 与其他再灌注治疗相比死亡率较低,但统计学上无显著差异。
再灌注治疗、入院类型、年龄、肾小球滤过率、心率和血压与 30 天死亡率独立相关。建议建立一个全面的 STEMI 网络以提高再灌注治疗率,特别是药物溶栓联合 PPCI 治疗率。